论文部分内容阅读
结直肠癌是最常见的恶性肿瘤之一,结直肠癌的肝脏转移是造成结直肠癌患者死亡的最主要原因之一。超过50%的结直肠癌患者会发生肝脏转移,其治疗的疗效直接影响着结直肠癌患者的预后。对于结直肠癌肝转移的患者行最佳支持治疗,患者的中位生存时间大约为6个月;行甲酰四氢叶酸钙(CF)+5-FU化疗,患者的中位生存时间为8～12个月;应用奥沙利铂或伊立替康的联合化疗(FOLFOX或FOLFIRI),其中位生存时间可延长至20～24个月。
Colorectal cancer is one of the most common malignant tumors. Liver metastasis of colorectal cancer is one of the most important causes of death in colorectal cancer patients. More than 50% of patients with colorectal cancer will develop liver metastases, the efficacy of its treatment directly affects the prognosis of patients with colorectal cancer. The median survival time for patients with colorectal cancer with liver metastases was approximately 6 months. The median survival time for patients treated with leucovorin (CF) + 5-FU was 8 ~ 12 months; with oxaliplatin or irinotecan in combination with chemotherapy (FOLFOX or FOLFIRI), the median survival time can be extended to 20 to 24 months.